Copyright: ©Author(s) 2026.
World J Virol. Sep 25, 2026; 15(3): 121081
Published online Sep 25, 2026. doi: 10.5501/wjv.121081
Published online Sep 25, 2026. doi: 10.5501/wjv.121081
| No risk | Low risk | High risk | Highest risk |
| Aminosalicylates | Vedolizumab | Corticosteroids | Tofacitinib (10 mg) |
| Budesonide | Ustekinumab | Azathioprine | Upadacitinib |
| 6-mercaptopurine | Anti-TNF + TP | ||
| Infliximab | 3 drug regimens | ||
| Adalimumab | |||
| Tofacitinib (5 mg) |
- Citation: Manrai M, Pachisia AV, Jha AA, Shukla R, Hande V, Thareja S. Herpes zoster vaccination in inflammatory bowel disease: Evidence, guidelines, and reality. World J Virol 2026; 15(3): 121081
- URL: https://www.wjgnet.com/2220-3249/full/v15/i3/121081.htm
- DOI: https://dx.doi.org/10.5501/wjv.121081